Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 10/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.35 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6889018 | 0.78 | YTHDC1 (0.35) | PIK3CAHDAC1 | |
| SCHEMBL6889089 | 0.74 | KMT2A (0.46) | MEN1KMT2APIK3CAMTORPIK3CG | |
| SCHEMBL9937767 | 0.71 | PIK3CA (0.43) | PIK3CAHDAC1 | |
| SCHEMBL6899031 | 0.68 | PDE10A (0.41) | MEN1KMT2APIK3CAHDAC1ALDH1A1 | |
| SCHEMBL4996765 | 0.66 | MTOR (0.61) | PIK3CAMTORPIK3CGRPTORMLST8 | |
| SCHEMBL18050664 | 0.65 | YTHDC1 (0.39) | — | |
| SCHEMBL3989427 | 0.65 | MTOR (0.52) | PIK3CAMTORPIK3CGRPTORMLST8 | |
| SCHEMBL4988909 | 0.65 | MTOR (0.64) | PIK3CAHDAC1MTORPIK3CGRPTOR | |
| SCHEMBL4993573 | 0.65 | MTOR (0.66) | PIK3CAMTORPIK3CGRPTORMLST8 | |
| SCHEMBL3428690 | 0.65 | PIK3CA (0.81) | PIK3CAMTORPIK3CGPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ADORA3, ADORA2A, ADORA2B | MEN1 1776/4885KMT2A 3059/4885PIK3CA 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.